3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
3
Recruiting
2
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
26
Lymphoma, Large B-Cell, Diffuse
19
Burkitt Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, T-Cell, Peripheral
8
Lymphoma, Follicular
8
Lymphoma, B-Cell
7
Lymphoma
7
Neoplasms
5
Lymphoma, Non-Hodgkin
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Leukemia, Biphenotypic, Acute
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Ovarian Neoplasms
2
Myasthenia Gravis
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Interventions
enzalutamide
5
darolutamide
4
Docetaxel
3
Prednisone
2
olaparib
1
gedatolisib
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
TVB-2640
1
Radiosurgery
1
Omeprazole
1
Dexamethasone
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms, Castration-Resistant
×
Prednisone
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled
NCT07225946
2026-05-11
KLK2-PASenger
Janssen Research & Development, LLC
Phase 3
Recruiting
800 enrolled